Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy
Status:
Completed
Trial end date:
2021-05-19
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if the combination of AvastinTM
(bevacizumab) and Tarceva (erlotinib hydrochloride) can help to control advanced liver
cancer. The safety of this drug combination will also be studied.